Pharma startup Passage Bio hires Gwendolyn Fisher to build comms team | PR Week
Gene Therapy Biotech Passage Bio IPOs | The Motley Fool
Passage Bio expands its R&D alliance and exclusive licensing relationship with Penn after its record-setting IPO - Penn Center for Innovation
Passage Bio went public during the stock market's worst week since 2008
Xconomy: Passage Bio Plans IPO as Three Gene Therapies Approach the Clinic
Passage Bio and CEO Bruce Goldsmith part ways - Philadelphia Business Journal
Passage Bio - Funding, Financials, Valuation & Investors
Gene Therapy Developer Passage Bio Files for $125M IPO
Here's Why Shares of Passage Bio Dropped Today | The Motley Fool
Joshua Puskar, CPA - Controller - Passage Bio | LinkedIn
Gene Therapy Developer Passage Bio Files for $125M IPO
Fenwick Represents Passage Bio in Initial Public… | Fenwick & West LLP
Final tally for Philadelphia-based Passage Bio's IPO: $248.4M - Philadelphia Business Journal
Passage Bio Stock: Worth Keeping An Eye On (NASDAQ:PASG) | Seeking Alpha
Passage Bio Stock: Worth Keeping An Eye On (NASDAQ:PASG) | Seeking Alpha
IPO ROUND-UP - Proactive Investors
IPO Roundup: Passage Bio Inc, Zhongchao Inc
Passage Bio slapped with gene therapy clinical hold | Fierce Biotech
Despite Market Drama, Passage Bio Launches $216 Million IPO | BioSpace
Passage Bio plans for IPO
As Genetics Firm Passage Bio Goes Public, Here Are The Investors Who Stand To Gain — Or Lose — The Most | CB Insights Research
IPO Update: Passage Bio Finalizes $126 Million IPO Plan (NASDAQ:PASG) | Seeking Alpha
Passage Bio chips away at workforce, prioritizes R&D with UPenn's James Wilson | Fierce Biotech
Gene therapy heats Passage Bio IPO; new Hatch Fund; rivals join BrokerTech; FS spins AIX; PCI buys, may sell
Passage Bio Announces Pricing of Initial Public Offering
Xconomy: Passage Bio's IPO Raises $216M to Fund Gene Therapy Studies
